ClinicalTrials.gg

Program

luvometinib

Also written as “luvometinib + anlotinib”, “FCN-159” and “Luvometinib Tablets”.

Its studies are mostly in Neurofibromatosis 1 · Neoplasm Metastasis · Histiocytosis, Langerhans-Cell, led by Fosun Pharma.

Furthest: phase 3, since Jun 6, 20236 company-led studies, 6 open or runningNext primary completion: Apr 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma66 open or runningphase 3since Jun 6, 2023Jun 17, 2021Apr 30, 2027phase 3 · NCT07004075

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 17, 2021First study: phase 2 study in Neurofibromatosis 1First studyNCT04954001 · 160 enrolled · United States, China, Spain
  2. Jun 6, 2023Phase 3 study in Neurofibromatosis 1NCT05913037 · 167 enrolled · China
  3. Aug 8, 2023Phase 2 study in Histiocytosis, Langerhans-CellNCT05997602 · 56 planned · China
  4. Jun 3, 2025Phase 2 study in Neurofibromatosis 1NCT07024394 · 65 planned · China
  5. Jun 3, 2025Phase 3 study in Low-grade GliomaNCT07004075 · 102 planned · China
  6. Apr 25, 2026Phase 2 study in Neoplasm MetastasisNCT07562581 · 48 planned · China

Ahead

  1. Apr 30, 2027Primary completion: phase 3 study in Low-grade GliomaNCT07004075
  2. Jun 2029Primary completion: phase 2 study in Neoplasm MetastasisNCT07562581
  3. Sep 23, 2029Primary completion: phase 2 study in Neurofibromatosis 1NCT07024394

TargetBeta

MAP2K1 →read by rule
“* Luvometinib is a selective oral MEK1/2 inhibitor.”study text, by rule · the study

Other programs on MAP2K1

ProgramCompanyFurthest phaseStudies
cobimetinibruleHoffmann-La Rochephase 338
pimasertibruleMerck KGaA, Darmstadt, Germanyphase 213
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 29
polfurmetinibPfizerphase 13

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07562581Neoplasm Metastasis · China2RecruitingJun 202948
NCT07024394Neurofibromatosis 1 · China2Not yet recruitingSep 23, 202965
NCT07004075Low-grade Glioma · China3Not yet recruitingApr 30, 2027102
NCT05997602Histiocytosis, Langerhans-Cell · China2RecruitingMay 14, 202556
NCT05913037Neurofibromatosis 1 · China3Active, not recruitingAug 19, 2025167
NCT04954001Neurofibromatosis 1 · United States, China, Spain2Active, not recruitingFeb 28, 2025160

How it is read

Names in the registry

  • “luvometinib + anlotinib”, 2 entries
  • “FCN-159”, 2 entries
  • “Luvometinib Tablets”, 1 entry
  • “Luvometinib”, 1 entry
  • “Test group (Group A): FCN-159 8 mg, orally, once daily;”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.